The Uromigos
The Uromigos
The UromigosThe Uromigos | June 1, 2023
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
Listen Now
The UromigosThe Uromigos | June 1, 2023
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
The UromigosThe Uromigos | May 23, 2023
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
The UromigosThe Uromigos | May 16, 2023
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
The UromigosThe Uromigos | May 9, 2023
We discuss new data in bladder cancer and more presented at the 2023 American Urological Association Annual Meeting.
The UromigosThe Uromigos | May 3, 2023
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
The UromigosThe Uromigos | April 25, 2023
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
The UromigosThe Uromigos | April 21, 2023
Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing.
The UromigosThe Uromigos | April 18, 2023
The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil.
The UromigosThe Uromigos | April 17, 2023
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The UromigosThe Uromigos | April 7, 2023
Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields.
The UromigosThe Uromigos | March 28, 2023
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The UromigosThe Uromigos | March 22, 2023
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
The UromigosThe Uromigos | March 17, 2023
Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities.
The UromigosThe Uromigos | March 7, 2023
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The UromigosThe Uromigos | February 27, 2023
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
The UromigosThe Uromigos | February 21, 2023
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
The UromigosThe Uromigos | February 21, 2023
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
The UromigosThe Uromigos | February 21, 2023
Christian Kollmannsberger, MD, FRCPC, discusses his presentation on utilizing miR371 as a biomarker for germ cell tumors.
The UromigosThe Uromigos | February 18, 2023
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.